Study of Safety and Efficacy of C-CAR011 in B-NHL Patients
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
Refractory or Relapsed Non-Hodgkin Lymphoma
BIOLOGICAL: C-CAR011
Safety(Incidence of adverse events), Incidence of adverse events (AEs), 12 weeks|Objective response rate (ORR), 12 weeks
Objective response rate (ORR), 12 months|Duration of remission(DOR), 12 months|Progression free survival(PFS), 12 months|Overall survival(OS), 12 months
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.